Lung cancer is staged using a combination of imaging scans, tissue samples, and sometimes surgery to determine how large the tumor is, whether it has reached nearby lymph nodes, and whether it has spread to distant organs. The staging system assigns a number from I to IV, with higher numbers indicating more advanced disease. This stage is the single most important factor in determining treatment options and expected outcomes.
The TNM System Explained
Doctors stage most lung cancers using the TNM system, which evaluates three things: the size and extent of the primary tumor (T), whether cancer cells have reached nearby lymph nodes (N), and whether cancer has spread, or metastasized, to other parts of the body (M). Each letter gets a number or descriptor, and those three values combine to produce an overall stage from I through IV.
The T category ranges from T1 (a smaller tumor confined to the lung) through T4 (a very large tumor or one that has grown into critical nearby structures like the heart, spine, or major blood vessels). Size thresholds matter: tumors are measured in centimeters, and each increase in size can bump the classification up. A tumor 3 cm or smaller falls into T1, while anything over 7 cm is classified as T4.
The N category tracks lymph node involvement. N0 means no lymph nodes contain cancer. N1 means cancer has reached nodes near the affected lung. N2 indicates spread to lymph nodes in the center of the chest (the mediastinum) on the same side as the tumor. N3 means nodes on the opposite side of the chest or above the collarbone are involved, which signals more advanced disease.
The M category is straightforward: M0 means no distant spread, while M1 means cancer has been found in the other lung, in fluid around the lung or heart, or in distant organs like the brain, bones, liver, or adrenal glands.
How Overall Stages Are Assigned
The TNM values are combined into an overall stage grouping. Stage I cancers are small tumors with no lymph node involvement and no distant spread. Stage II includes slightly larger tumors or those with limited spread to nearby lymph nodes. Stage III covers a wide range of situations where the tumor has grown into surrounding structures or reached mediastinal lymph nodes. Stage IV means cancer has metastasized to distant sites.
Each stage also has substages (like IIIA versus IIIB) that create finer distinctions. These substages can mean the difference between being a candidate for surgery and needing a different treatment approach entirely.
Small Cell Lung Cancer Uses a Simpler System
Small cell lung cancer, which accounts for about 10 to 15 percent of all lung cancers, is staged differently. Instead of the full TNM breakdown, it is classified as either limited stage or extensive stage. Limited-stage disease means cancer is only on one side of the chest and can be targeted with a single radiation field. It may include lymph nodes on the same side, including those above the collarbone. Extensive-stage disease means cancer has spread beyond that boundary, whether to the other lung, to distant organs, or into fluid around the lungs. Most people with small cell lung cancer are diagnosed at the extensive stage.
Tests Used to Determine the Stage
Staging relies on several types of tests, usually done in a specific sequence. The process typically starts with a CT scan of the chest and upper abdomen. If that scan shows a suspicious mass, a PET-CT scan is the next step. PET-CT works by detecting areas of unusually high metabolic activity, which cancer cells tend to produce. For identifying lymph node involvement in non-small cell lung cancer, PET-CT has an overall sensitivity of about 85% and specificity of 84%. That means it catches most affected lymph nodes, but it can occasionally light up from inflammation or infection rather than cancer.
Because PET-CT isn’t perfect, suspicious lymph nodes often need to be sampled directly. This can be done through a procedure called endobronchial ultrasound (EBUS), where a thin scope is passed through the airway to reach lymph nodes with a needle. The older approach, mediastinoscopy, requires a small incision in the neck. Both methods have similar accuracy, but EBUS has a significantly lower complication rate and can access a wider range of lymph node locations, including some that mediastinoscopy simply cannot reach.
Brain MRI is also part of staging for most people. Guidelines recommend brain imaging for anyone with non-small cell lung cancer beyond the very earliest stage (stage IA). Brain metastases can be present even without symptoms, so this scan catches spread that would otherwise go undetected and change the entire treatment plan.
Clinical Stage vs. Pathological Stage
You may hear two different stage designations during your care. The clinical stage is determined before any surgery, based on physical exams, biopsies, and imaging. This is the stage used to plan initial treatment. If surgery is performed, the pathological stage (also called the surgical stage) is then determined by examining the actual tissue removed during the operation, including the tumor itself and surrounding lymph nodes.
The pathological stage is considered more accurate because it is based on direct examination of tissue under a microscope rather than images. It is not uncommon for the pathological stage to differ from the clinical stage. A tumor that looked confined on imaging might turn out to have microscopic spread to a lymph node, bumping the stage up. Occasionally the opposite happens, and the pathological stage is lower than expected.
How Biomarker Testing Fits In
Staging tells you how far the cancer has spread, but biomarker testing tells you what’s driving it at a molecular level. For anyone diagnosed with non-small cell lung cancer, especially at an advanced stage, testing for specific genetic mutations and protein markers has become standard. Nearly all oncologists now order tests for mutations in genes like EGFR, ALK, ROS1, and BRAF.
These results don’t change the TNM stage, but they directly shape treatment. Cancers with certain mutations can be treated with targeted therapies that are often more effective and have fewer side effects than traditional chemotherapy. A multi-gene panel test, called next-generation sequencing, can check for many of these mutations at once using a single tissue sample. For advanced-stage patients, having biomarker results at the time treatment decisions are being made is critical to getting the most appropriate therapy from the start.
What Staging Means for Survival
Stage at diagnosis is strongly linked to outcomes. Data from the SEER database, which tracks cancer cases across the United States, shows clear differences in five-year relative survival rates based on how far the cancer has spread at the time of diagnosis:
- Localized (cancer confined to the lung): 65.5%
- Regional (spread to nearby lymph nodes): 38.2%
- Distant (cancer has metastasized): 10.5%
These are population-level averages from 2016 to 2022, so they reflect a mix of ages, tumor types, and treatments. Individual outcomes vary based on the specific tumor biology, biomarker profile, overall health, and how well the cancer responds to treatment. Survival rates have been improving in recent years as targeted therapies and immunotherapies have become more widely used, particularly for advanced-stage disease. The numbers above may underestimate current outcomes for people starting treatment today.
Why Accurate Staging Matters
Getting the stage right determines everything that follows. A stage I cancer may be curable with surgery alone. A stage III cancer might require a combination of chemotherapy, radiation, and possibly surgery, in a carefully planned sequence. Stage IV disease is typically treated with systemic therapies, where biomarker results become especially important for choosing the right drug.
Staging can also be revised. If cancer returns after treatment or progresses, it is restaged using the same tools: new scans, possibly new biopsies, and updated biomarker testing. The restaged classification then guides the next round of treatment decisions.